Barcelona-based Biorce closes €43.8 million Series A to accelerate AI-driven clinical trials

Barcelona-based HealthTech company Biorce has secured a significant €43.8 million Series A funding round, marking a substantial investment in AI-driven clinical trial optimization. This funding, bolstered by new and existing investors including DST Global Partners and Norrsken VC, will fuel Biorce's international expansion and accelerate its product development efforts. The substantial investment underscores growing confidence in AI's capacity to address long-standing inefficiencies within the pharmaceutical research sector, potentially hastening patient access to vital treatments. Biorce's innovative approach centers on its proprietary AI platform, Aika, designed to reduce clinical trial preparation timelines and minimize costly protocol amendments, which often lead to significant delays. The platform leverages a robust dataset of approximately one million clinical trials to enhance protocol development, site selection, and feasibility assessments, aiming to cut trial costs by over 50%. Aika's distinctive "human-in-the-loop" architecture ensures that AI-generated recommendations are accompanied by transparent documentation, allowing for defensibility before regulatory bodies like the FDA and EMA. This funding round, the largest of its kind in the Iberian HealthTech and AI ecosystem, directly impacts pharmaceutical companies, biotech firms, and Contract Research Organizations (CROs) by offering a solution to the estimated €101.2 billion global annual spend on clinical trial management. By accelerating the development of new therapies across various therapeutic areas, Biorce's technology contributes to a more efficient and cost-effective drug development pipeline, aligning with broader European goals for digital sovereignty in critical sectors like healthcare. The company has now raised over €50.6 million in total funding, positioning it for significant growth and impact.